Brief: OSE Immunotherapeutics Appoints Thomas Gidoin As Chief Financial Officer
20/08/2025 17:34
Aug 20 (Reuters) - OSE Immunotherapeutics SA OSE.PA: OSE IMMUNOTHERAPEUTICS APPOINTS THOMAS GIDOIN AS CHIEF FINANCIAL OFFICER OSE IMMUNOTHERAPEUTICS SA - THOMAS GIDOIN SUCCEEDS ANNE-LAURE AUTRET-CORNET AS CFO Source text: ID:nGNX26S6XW Further company coverage: OSE.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO